On Tuesday, Fulcrum Therapeutics Inc (NASDAQ: FULC) was -7.84% drop from the session before settling in for the closing price of $10.84. A 52-week range for FULC has been $2.32 – $15.74.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 54.59%. When this article was written, the company’s average yearly earnings per share was at -629.38%. With a float of $59.86 million, this company’s outstanding shares have now reached $65.97 million.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Fulcrum Therapeutics Inc stocks. The insider ownership of Fulcrum Therapeutics Inc is 9.27%, while institutional ownership is 67.40%. The most recent insider transaction that took place on Jan 02 ’26, was worth 178,089. In this transaction Director of this company sold 15,000 shares at a rate of $11.87, taking the stock ownership to the 469,864 shares. Before that another transaction happened on Dec 15 ’25, when Company’s Chief Legal Officer sold 3,452 for $12.92, making the entire transaction worth $44,600. This insider now owns 10,252 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.31 earnings per share (EPS) during the time that was less than consensus figure (set at -0.29) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -629.38% per share during the next fiscal year.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
You can see what Fulcrum Therapeutics Inc (FULC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.19 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
The latest stats from [Fulcrum Therapeutics Inc, FULC] show that its last 5-days average volume of 0.8 million was superior to 0.72 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 10.79%.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 38.77%, which indicates a significant increase from 5.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.70 in the past 14 days, which was higher than the 0.69 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.51, while its 200-day Moving Average is $7.50. Now, the first resistance to watch is $10.56. This is followed by the second major resistance level at $11.14. The third major resistance level sits at $11.52. If the price goes on to break the first support level at $9.61, it is likely to go to the next support level at $9.23. The third support level lies at $8.65 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
There are 54,118K outstanding shares of the company, which has a market capitalization of 659.04 million. As of now, sales total 80,000 K while income totals -9,730 K. Its latest quarter income was 0 K while its last quarter net income were -19,600 K.
